USFDA conducts inspection at Cipla’s Indore facility

18 May 2019 Evaluate

The United States Food and Drug Administration (USFDA) has conducted a post-approval inspection at Cipla’s Indore facility from May 13 - 17, 2019. The inspection ended with zero observations.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Cipla Share Price

1466.05 -0.10 (-0.01%)
12-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1736.85
Dr. Reddys Lab 1215.65
Cipla 1466.05
Zydus Lifesciences 895.00
Lupin 2189.75
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×